Insider Trading April 21, 2026 05:40 PM

SoftVest Increases Stake in Cross Timbers Royalty Trust with $343,161 Purchase

Two transactions in April boost SoftVest’s holdings as CRT trades near its 52-week high

By Leila Farooq CRT
SoftVest Increases Stake in Cross Timbers Royalty Trust with $343,161 Purchase
CRT

SoftVest, LP, a reported 10% owner of Cross Timbers Royalty Trust (CRT), added 32,893 units of beneficial interest across two April transactions for a combined outlay of $343,161. The purchases occurred at weighted average prices between $10.38 and $10.44 per unit, bringing SoftVest’s holdings to 791,105 units as CRT trades near $10.59, close to its 52-week peak of $11.10.

Key Points

  • SoftVest, LP purchased a total of 32,893 Cross Timbers Royalty Trust units in two transactions for $343,161, at weighted average prices of $10.44 and $10.38 per unit.
  • After the April 17 and April 20, 2026 transactions, SoftVest, LP’s holdings rose to 791,105 units of beneficial interest in CRT.
  • CRT is trading at $10.59, near its 52-week high of $11.10, and has gained 54% over the last six months; InvestingPro analysis cited in the filings reports CRT appears overvalued relative to its Fair Value estimate.

SoftVest, LP - identified in regulatory filings as a 10% owner of Cross Timbers Royalty Trust (CRT) - expanded its position in the trust in April through two separate buy transactions totaling $343,161.

On April 17, 2026, SoftVest, LP acquired 28,861 units at a weighted average price of $10.44 per unit. Those securities were purchased across multiple trades at prices ranging from $10.26 to $10.50. After that purchase, SoftVest, LP’s reported holding stood at 787,073 units of beneficial interest.

A few days later, on April 20, 2026, SoftVest, LP added another 4,032 units, paying a weighted average price of $10.38 per unit. Those shares were purchased in transactions priced between $10.35 and $10.40. Following the April 20 transaction, SoftVest, LP’s holdings increased to 791,105 units of beneficial interest.

The two acquisitions together equal 32,893 units and amount to $343,161 in purchase value, with weighted average prices reported in the $10.38 to $10.44 per-unit range.

At present CRT is trading at $10.59, a level close to its 52-week high of $11.10. The trust has risen 54% over the past six months. According to InvestingPro analysis cited in the filings, CRT presently appears overvalued relative to its Fair Value estimate; the platform also notes that users can access valuation metrics and ProTips for the trust through its service.

The units are directly held by SoftVest, LP. SoftVest GP I, LLC serves as the general partner of SoftVest, LP, and Eric L. Oliver is identified as the managing member of SoftVest GP I, LLC. By virtue of those relationships, both SoftVest GP I, LLC and Mr. Oliver may be deemed to beneficially own the securities held by SoftVest, LP, although Mr. Oliver disclaims beneficial ownership except to the extent of his pecuniary interest.


The filing provides a clear snapshot of the recent insider purchasing activity and the ownership structure behind the buyer, while also noting valuation context and recent market performance for CRT.

Risks

  • Valuation risk - InvestingPro analysis indicates CRT may be overvalued relative to its Fair Value estimate, which could affect investor returns and trading activity in the trust.
  • Price concentration risk - SoftVest’s position represents a sizeable holding (reported as a 10% owner), and changes in its stake could influence market perception and liquidity for CRT units.
  • Short-term market volatility - CRT’s price is trading near its 52-week high following a 54% six-month gain, exposing investors to potential pullbacks or increased volatility.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026